Adaptive Biotechnologies (ADPT) Operating Expenses (2018 - 2025)
Adaptive Biotechnologies (ADPT) has disclosed Operating Expenses for 8 consecutive years, with $84.5 million as the latest value for Q4 2025.
- Quarterly Operating Expenses rose 3.88% to $84.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $334.1 million through Dec 2025, down 2.17% year-over-year, with the annual reading at $334.1 million for FY2025, 2.17% down from the prior year.
- Operating Expenses hit $84.5 million in Q4 2025 for Adaptive Biotechnologies, up from $83.7 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $116.9 million in Q4 2023 to a low of $79.1 million in Q3 2024.
- Historically, Operating Expenses has averaged $91.1 million across 5 years, with a median of $90.6 million in 2024.
- Biggest five-year swings in Operating Expenses: skyrocketed 52.46% in 2021 and later tumbled 30.43% in 2024.
- Year by year, Operating Expenses stood at $99.5 million in 2021, then decreased by 5.17% to $94.4 million in 2022, then grew by 23.8% to $116.9 million in 2023, then crashed by 30.43% to $81.3 million in 2024, then rose by 3.88% to $84.5 million in 2025.
- Business Quant data shows Operating Expenses for ADPT at $84.5 million in Q4 2025, $83.7 million in Q3 2025, and $83.9 million in Q2 2025.